#Weekly Sharing 28 May

$Dow Jones Industrial Average (.DJI.US)$ -1.85% , $S&P 500 Index (.SPX.US)$ -0.06%, $Nasdaq Composite Index (.IXIC.US)$ +0.75%

The Nasdaq closed slightly higher this week, driven by gains in chipmaker $NVIDIA (NVDA.US)$, despite concerns that the Federal Reserve might delay interest rate cuts. The market maintains bullish sentiment towards AI giants and other tech names, even as worries persisted about the Fed not lowering rates this summer.

Events to watch
- US CB Consumer Confidence - May 28
- US GAP - May 30th
- US Core PCE price index - May 31th

$FTSE Bursa Malaysia KLCI Index (.KLSE.MY)$ decreased slightly by 0.498% and ended at 1619.4
Notable sectors : Hardware +7.78%, Media diversified +6.89%, Semiconductors +6.56%

Events to watch
- MY Money Supply May 31st

Moderna had a 25.36% increase last week due news of first-ever detection of avian bird flu in Australia, raising concerns about a potential outbreak and possibly benefiting companies capable of rapidly producing a bird flu vaccine.

Price trend
The biotech company thrived in the COVID-19 vaccine market, investors correctly anticipated a decline in this niche and began selling off the stock in early 2022, peaking at 454.60 in Sept 2021.
However, Moderna has experienced a 45.38% increase from the start of May, closing last week at $166.61.

Company profile
Moderna, Inc. is a biotechnology company that discovers, develops, and commercializes messenger RNA therapeutics and vaccines. Their treatments target infectious diseases, immuno-oncology, rare diseases, autoimmune disorders, and cardiovascular diseases across the United States, Europe, and internationally.

Current projects
Moderna is developing mRNA-1345, a vaccine targeting the respiratory syncytial virus (RSV), which infects the lungs and respiratory tracts. The company is also conducting phase 3 studies for a combination COVID-19/flu vaccine, a cytomegalovirus vaccine (currently, there are no approved vaccines in this area), and a personalized cancer vaccine.

Risks
Earlier this month, the FDA notified Moderna of a delay due to administrative constraints. Brand-new products have a limited shelf life before their patent protection expires. The less time they spend on the market, the less revenue they will generate in sales.

Text Disclaimer
This content is for reference only and does not constitute any investment advice, and past performance is not indicative of future performance. Returns will vary, and all investments carry risks, including loss of principal. Please make your own investment decisions.

And for today’s video tutorial, i am gonna share how to use technical analysis tools in moomooo. Check it out👇

Video Disclaimer
This video is provided for informational purposes only. No content in the video shall be considered a recommendation or solicitation for the purchase or sale of financial products. Moomoo MY does not provide financial advice. Please assess your risks and consult your financial adviser.